THE FOURTH INTERNATIONAL AIDS MALIGNANCY CONFERENCE
Natcher Conference Center, National Institutes of Health, Bethesda, Maryland
May 16-18, 2000

Program

May 16

8:00 AM-6:00 PM  POSTER PRESENTATIONS (Abstract Numbers 11 to 34), First Floor Concourse

8:30 AM  Opening Remarks and Welcome
Ellen Feigal, M.D., National Cancer Institute

8:45 AM  PLENARY LECTURE
S1 Harnessing the Immune System in the Fight Against AIDS
Bruce Walker, M.D., Harvard University

9:10 AM  ROUNDTABLE - Epidemiology of AIDS Malignancies
Chairs:
Elizabeth Holly, M.D., University of California, San Francisco
Jeffrey Jones, M.D., Centers for Disease Control and Prevention

Panelists:
S2 International Collaboration on HIV and Cancer
Gillian Reeves, Ph.D., Imperial Cancer Research Fund, United Kingdom
Robert Newton, M.B.B.S., D.Phil., Imperial Cancer Research Fund, United Kingdom
Valerie Beral, M.B.B.S., Imperial Cancer Research Fund, United Kingdom

S3 The National AIDS-Cancer Match Registry
Robert Biggar, M.D., National Cancer Institute

S4 Risk for Hepatocellular Carcinoma and Non-Hodgkin's Lymphoma Among HIV-infected Adults
Eric Engels, M.D., M.P.H., National Cancer Institute

S5 Human Papillomavirus-associated Anogenital Cancers in Patients with HIV Infection and AIDS
Morten Frisch, M.D., Ph.D., Statens Serum Institut, Denmark

10:40 AM  Break

11:00 AM-11:45 AM  ABSTRACT PRESENTATIONS - AIDS Malignancies: Epidemiology and Immunology
Moderators:
Robert Biggar, M.D., National Cancer Institute
David Scadden, M.D. Harvard University
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 AM</td>
<td>National Linkage of HIV, AIDS, and Cancer Incidence Data</td>
</tr>
<tr>
<td></td>
<td>Andrew Grulich, Ph.D., <em>National Centre in HIV Epidemiology and Clinical Research, Australia</em></td>
</tr>
<tr>
<td>11:15 AM</td>
<td>The Spectrum of HIV-1 Related Cancers in South Africa</td>
</tr>
<tr>
<td></td>
<td>Freddy Sitas, D.Phil., <em>National Cancer Registry, South Africa</em></td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Non-myeloablative Allogeneic Transplantation of Genetically Modified PBSCs for Hematologic Malignancies</td>
</tr>
<tr>
<td></td>
<td>Elizabeth Kang, M.D., <em>National Institute of Diabetes and Digestive and Kidney Disorders</em></td>
</tr>
<tr>
<td>11:45 AM</td>
<td>Lunch (on your own)</td>
</tr>
<tr>
<td>1:15 PM</td>
<td>ROUNDTABLE - Kaposi’s Sarcoma Herpesvirus (KSHV/HHV-8) Transmission <em>In Vivo and In Vitro</em></td>
</tr>
<tr>
<td></td>
<td>Chairs:</td>
</tr>
<tr>
<td></td>
<td>Harold Jaffe, M.D., <em>Centers for Disease Control and Prevention</em></td>
</tr>
<tr>
<td></td>
<td>Gary Hayward, Ph.D., <em>Johns Hopkins University</em></td>
</tr>
<tr>
<td></td>
<td>Panelists:</td>
</tr>
<tr>
<td>S6</td>
<td>In Vitro Transmission and Propagation of HHV-8 in Endothelial Cells</td>
</tr>
<tr>
<td></td>
<td>Gary Hayward, Ph.D., <em>Johns Hopkins University</em></td>
</tr>
<tr>
<td>S7</td>
<td>Transmission of HHV-8 Among Homosexual Men</td>
</tr>
<tr>
<td></td>
<td>Jeffrey Martin, M.D., M.P.H., <em>University of California, San Francisco</em></td>
</tr>
<tr>
<td>S8</td>
<td>Natural History of HHV-8 Infection in an Endemic Population: Evidence for Mother-Child and Sibling-Sibling Transmission</td>
</tr>
<tr>
<td></td>
<td>Antoine Gessain, M.D., Ph.D., <em>Pasteur Institute, France</em></td>
</tr>
<tr>
<td>S9</td>
<td>Evidence for Heterosexual Transmission of HHV-8 in South Africa</td>
</tr>
<tr>
<td></td>
<td>Freddy Sitas, D.Phil., <em>Cancer Registry, South Africa</em></td>
</tr>
<tr>
<td>S10</td>
<td>HHV-8 Anatomic Sites, Shedding Patterns, Behavioral and Biological Risk Factors for Transmission</td>
</tr>
<tr>
<td></td>
<td>Lawrence Corey, M.D., <em>University of Washington</em></td>
</tr>
<tr>
<td>S11</td>
<td>In Vitro Infection of Primary Human Endothelial, Epidermal, and Lymphoid Cells by HHV-8</td>
</tr>
<tr>
<td></td>
<td>Ethel Cesarman, M.D., Ph.D., <em>Weill Medical College of Cornell University</em></td>
</tr>
<tr>
<td>S12</td>
<td>HHV-8 Infection and Growth Regulation of Dermal Microvascular Endothelial Cells</td>
</tr>
<tr>
<td></td>
<td>Ashlee Moses, Ph.D., <em>Oregon Health Sciences University</em></td>
</tr>
<tr>
<td>2:25 PM</td>
<td>Break</td>
</tr>
</tbody>
</table>
2:45 PM-4:30 PM  ABSTRACT PRESENTATIONS - KSHV/HHV-8: Transmission and In Vitro Virus/Cell Interactions
Moderators:
Parkash Gill, M.D., University of Southern California and Norris Cancer Hospital
James Goedert, M.D., National Cancer Institute

2:45 PM  4 Evidence of Blood-borne Transmission of HHV-8 Among Women With HIV Risk Behaviors
Michael Cannon, M.S., Centers for Disease Control and Prevention

3:00 PM  5 Mixed Latent and Lytic Cycle Infection of Primary Human Dermal Microvascular Endothelial Cells With HHV-8 Derived from the JCS1 PEL Cell Line
Gary Hayward, Ph.D., Johns Hopkins School of Medicine

3:15 PM  6 HHV-8/KSHV Regulation of Endothelial Cell Growth and Differentiation Pathways
Ashlee Moses, Ph.D., Oregon Health Sciences University

3:30 PM  7 Characterization of Hematopoietic Progenitor Cells Following in Vitro Infection by KSHV
Judy Mikovits, Ph.D., SAIC Frederick, Frederick Cancer Research and Development Center, National Cancer Institute

3:45 PM  8 Infection of Endothelial Cells with HHV-8 Leads to Induction of Cellular Antiviral Genes
Margaret Offerman, M.D., Ph.D., Emory University

4:00 PM  9 Infection of HHV-8-infected B Cell Lines With Cell-free HIV-1 Through the CXCR4 Chemokine Receptor
Elizabeth Read-Connole, M.S., Ph.D., National Cancer Institute

4:15 PM  10 The KSHV Latency-Associated Nuclear Antigen Mediates Episome Persistence Through Cis-acting KSHV Terminal Repeat (TR) DNA and Specifically Binds TR Sequence
Kenneth Kaye, M.D., Brigham and Women's Hospital, Harvard Medical School

4:30 PM-5:00 PM Authors at posters

4:30 PM-5:45 PM RECEPTION

May 17

8:00 AM- 6:30 PM POSTER PRESENTATIONS (Abstract Numbers 45 to 74), First Floor Concourse

8:30 AM  S13 PLENARY LECTURE
Translational Development of Vaccines Against B-Cell Malignancies
Larry Kwak, M.D., National Cancer Institute
8:55 AM-9:40 AM  **ABSTRACT PRESENTATIONS - Lymphomas: Transplantation and Clinical Aspects**  
Moderator:  
Alexandra Levine, M.D., *University of Southern California and Norris Cancer Hospital*

8:55 AM  35 Bone Marrow Transplant Recipient Post-transplantation Lymphoproliferative Disorders Differ From Those in Solid Organ Transplant Recipients  
Amy Chadburn, M.D., *Weill School of Medicine of Cornell University*

9:10 AM  36 TCL-1 Oncoprotein Expression and VH Gene Sequences in Primary Central Nervous Lymphoma  
Luigi Larocca, M.D., *Catholic University of Rome, Italy*

9:25 AM  37 Treatment of Relapsed/Refractory AIDS-related Lymphomas With High Dose Cytarabine (ARA-C) Cisplatin Combination Regimens  
Alexandra Levine, M.D., *University of Southern California and Norris Cancer Hospital*

9:40 AM  **PLENARY LECTURE**  
S14 Gamma Herpesvirus Targets for Therapy  
Elliott Kieff, M.D., *Harvard University*

10:05 AM  Break

10:25 AM  **ROUNDTABLE - New Directions in AIDS Lymphoma Treatment**  
Chairs:  
Richard Ambinder, M.D., Ph.D., *Johns Hopkins University*  
David Scadden, M.D., *Harvard University*

Panelists:  
S15 Infusional Cyclophosphamide, Doxorubicin, and Etoposide in HIV-Associated Non-Hodgkin's Lymphoma: A Review of the Einstein, Aviano, and ECOG Experience in 182 Patients  
Joseph Sparano, M.D., *Montefiore Cancer Center*

S16 Dose-Adjusted EPOCH Chemotherapy With Suspension of Antiretroviral Therapy for HIV-Associated Non-Hodgkin's Lymphoma  
Richard Little, M.D., *National Cancer Institute*

S17 Dose Adjusted Treatment in AIDS-Related Lymphoma  
Umberto Tirelli, M.D., *Aviano Cancer Center, Italy*

S18 Non-Myeloablative Bone Marrow Transplantation in the Treatment of Refractory Lymphomas  
Megan Sykes, M.D., *Harvard Medical School*

S19 Treatment of AIDS Lymphoma With High-Dose Chemotherapy and Genetically Modified Stem Cells: A Model for Evaluation of Gene Therapy  
John Zaia, M.D., *City of Hope National Medical Center*
11:55 AM  Lunch (on your own)

1:25 PM-2:10 PM  **ABSTRACT PRESENTATIONS - Lymphomas: KSHV/HHV-8**
Moderator: Richard Ambinder, M.D., Ph.D., *Johns Hopkins University*

1:25 PM  38 High Incidence of Non-Hodgkin's Lymphoma in HIV/HHV-8 Associated Castleman's Disease
Eric Oksenhender, M.D., *Hospital Saint-Louis, France*

1:40 PM  39 Proliferation in HHV-8 Positive Primary Effusion Lymphomas is Associated With Expression of HHV-8 Cyclin but Independent of P27/KIP1
Antonino Carbone, M.D., *Centro di Riferimento Oncologico-Aviano and Istituto Nazionale Tumori, Italy*

1:55 PM  40 Pharmacologic Induction of Lytic Infection: A Novel Therapeutic Strategy for EBV- and KSHV-associated Malignancies
Jennifer Cannon, M.S., *Johns Hopkins University School of Medicine*

2:10 PM  **ROUNDTABLE - KSHV/HHV-8 in Post-transplant Kaposi's Sarcoma**
Chairs:
Kenneth Cremer, Ph.D., *National Cancer Institute*
Thomas Schulz, M.D., *University of Liverpool, United Kingdom*

Panelists:
S20  Viral Infection and Malignancy in the Organ Transplant Recipient
Jay Fishman, M.D. *Massachusetts General Hospital*

S21  Risk Estimates and Subsequent Therapeutic Strategies in Posttransplant Kaposi's Sarcoma
Dominique Farge, M.D., *Hospital Saint-Louis, France*

Risk of Kaposi’s Sarcoma Development in Renal Transplant Patients from Northern Italy
Carlo Parravicini, M.D., *L. Sacco Hospital, Italy*

S22  Evidence for Reactivation of HHV-8 Among Solid Organ But Not Bone Marrow Transplant Patients
Frank Jenkins, Ph.D., *University of Pittsburgh Cancer Institute*

S23  Prevalence of Antibodies to HHV-8 in Saudi Arabians Patients With and Without Renal Failure
George Miller, M.D., *Yale University School of Medicine*

S24  Non Malignant Disease Associated With HHV-8 Infection in Peripheral Blood Stem Cell and Renal Transplant Patients From Italy
Mario Luppi, M.D., Ph.D., *University of Modena, Italy*

3:30 PM  Break
3:50 PM-4:50 PM  ABSTRACT PRESENTATIONS - KSHV/HHV-8: Molecular Biology
Moderator:
Thomas Schulz, M.D., University of Liverpool, United Kingdom

3:50 PM  41  KSHV Impairs Antigen Presentation in Latently Infected Cells
Christian Brander, Ph.D., Massachusetts General Hospital

4:05 PM  42  HHV-8 Open Reading Frame K1 Signals Through NFκB and Activates Cells
Felipe Samaniego, M.D., M.D. Anderson Cancer Center

4:20 PM  43  Novel HHV-8/CDK6 Kinase Substrates
Rukiyah Van Dross, Ph.D., Vanderbilt University

4:35 PM  44  Signal Transduction Pathways Involved in Reactivation of HHV-8 in Latently-infected Cells: Evidence for Distinct Calcineurin- and Protein Kinase C-dependent Pathways
Paul Zoeteweij, Ph.D., National Cancer Institute

4:50 PM-5:20 PM  Authors at posters

4:50 PM-6:00 PM  RECEPTION

May 18

8:30 AM  ROUNDTABLE - Approaches to Monitoring Therapy With Anti-angiogenesis Agents
Chairs:
Ellen Feigal, M.D., National Cancer Institute
Michal Neeman, Ph.D., The Weizmann Institute of Science, Israel

Panelists:
Angiogenesis: Clinical Perspectives
James Pluda, M.D., National Cancer Institute

Ultrasound in Evaluating Angiogenesis
Kathy Ferrara, Ph.D., University of California, Davis

S25  Monitoring Activity in Lesions of Kaposi's Sarcoma Using Infra-red Images
Jerry Williams, Ph.D., Johns Hopkins University

9:40 AM  PLENARY LECTURE
S26  Human Papillomavirus Infections in HIV Positive Adolescents
Anna-Barbara Moscicki, M.D., University of California, San Francisco

10:05 AM  Break

10:20 AM-11:05 AM  ABSTRACT PRESENTATIONS - Clinical Approaches
Moderators:
Joel Palefsky, M.D., F.C.R.P., University of California, San Francisco
Robert Yarchoan, M.D., National Cancer Institute
10:20 AM  75  Angiogenesis Inhibitor Col-3 in the Treatment of HIV-related Kaposi's Sarcoma: a Phase I AIDS Malignancy Consortium Study
   Mary Cianfrocca, D.O., Fox Chase Cancer Center

10:35 AM  76  Treatment of Human Papillomavirus Type 16 Virus-infected Cells Using the Herpes Simplex Virus Thymidine Kinase Gene
   Neerja Sethi, Ph.D., University of California, San Francisco

10:50 AM  77  Detection of Human Polyomavirus JC in Pediatric HIV-Associated Cancers
   Bruce Shiramizu, M.D., University of Hawaii at Manoa

PLENARY LECTURE/DISCUSSION
11:05 AM  Anal Squamous Intraepithelial Lesions: Therapeutic Challenges and Opportunities Session
   Joel Palefsky, M.D., F.C.R.P., University of California, San Francisco

11:45 AM  Lunch (on your own)

12:45 PM-3:30 PM  CURRENT SCIENCE IN SEROLOGIC TECHNIQUES FOR DETECTION OF KSHV/HHV-8
Sponsored by the Biological Carcinogenesis Branch, Division of Cancer Biology, National Cancer Institute
Chairs:
Kenneth Cremer, Ph.D., National Cancer Institute
Patrick Moore, M.D., M.P.H., Columbia University

Speakers:
78  Serological Assays for KSHV Based on Recombinant Viral Proteins
Thomas F. Schulz, M.D., University of Liverpool, United Kingdom

79  Comparison of HHV-8 Serologic Assays and Development of an Algorithm for HHV-8 Serodiagnosis
Frank Neipel, Ph.D., Universitat Erlangen, Germany

80  HHV-8 Peptide ELISA
Octavian Schatz, Ph.D., DIAVIR Limited, Germany

81  Selection of Reference Groups and Cut-points in the Development of HHV-8 Serologic Assays
Jeffrey Martin, M.D., M.P.H., University of California, San Francisco

82  Serological Responses to HHV-8
Bala Chandran, Ph.D., University of Kansas Medical Center

83  Serologic Assays for Detection of HHV-8 Antibodies
Philip E. Pellett, Ph.D., Centers for Disease Control and Prevention

84  Performance of HHV-8 Serological Assays for Testing Sera from Diverse Populations: Assay Development
Denise Whitby, Ph.D., Frederick Cancer Research and Development Center, National Cancer Institute
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Author(s)</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>84</td>
<td>Performance of HHV-8 Serological Assays for Testing Sera from Diverse Populations: Data Analysis</td>
<td>Eric Engels, M.D., M.P.H., National Cancer Institute</td>
<td></td>
</tr>
<tr>
<td>85</td>
<td>KSHV Serology in Europe and Uganda: A Multicentric Study with Multiple and Novel Assays</td>
<td>Paolo Monini, Ph.D., Instituto Superiore de Sanita, Italy</td>
<td></td>
</tr>
<tr>
<td>86</td>
<td>Multicenter Comparison of HHV-8 Serologic Assays and Assessment of HHV-8 Seroprevalence in US Blood Donors</td>
<td>Philip E. Pellett, Ph.D., Centers for Disease Control and Prevention</td>
<td></td>
</tr>
</tbody>
</table>